The Korea Disease Control and Prevention Agency (KDCA) has announced a groundbreaking advancement in dementia research. The National Institute of Health (NIH) under the KDCA has developed a new prognostic framework that categorizes the progression risk of Alzheimer’s disease into six distinct stages. This new system aims to overcome the limitations of the traditional diagnostic model, which relied primarily on three cognitive stages: cognitively normal, mild cognitive impairment (MCI), and dementia.

While the existing three-stage classification has been the clinical standard, it often failed to account for the significant variability in disease progression and deterioration rates among patients who shared the same cognitive status. To address this, researchers conducted an integrated analysis of clinical data from 1,263 participants in a Korean elderly dementia cohort. The study incorporated various parameters, including cognitive function test scores, blood biomarkers, brain imaging results, and the age of the participants.

The research, recently published in the prestigious international journal Nature Communications, revealed that as the disease progresses from 'Stage 0' to 'Stage IVB', the decline in both cognitive and daily functional abilities becomes significantly more pronounced.

The study identified key biomarkers essential for predicting progression risks at different stages of the disease. In the cognitively normal group, blood-based glial fibrillary acidic protein (GFAP) and phosphorylated tau (pTau217) were identified as the primary predictors. For those in the mild cognitive impairment group, hippocampal volume measured via MRI, along with pTau217 levels, proved to be critical. In patients already diagnosed with dementia, age and pTau217 emerged as the key factors distinguishing high-risk groups. Notably, blood pTau217 was found to be a consistent and reliable predictor of prognosis across the entire cycle of Alzheimer's disease.

It is important to note that this new 6-stage prognostic system is not intended to serve as a direct diagnostic tool for determining immediate medical treatment. Instead, it is designed to enhance precision in long-term patient management. A representative from the National Institute of Health stated, "We plan to actively utilize this predictive framework to establish customized prevention and management strategies. This includes the early identification of high-risk groups, focused follow-up monitoring and counseling, and setting priorities for future early-intervention clinical studies."

By moving beyond simple cognitive categorization and adopting a multidimensional prognostic approach, this study marks a significant step forward in personalized medicine for neurodegenerative diseases. As the global burden of dementia continues to rise, the ability to predict individual disease trajectories will be vital for improving the quality of life for patients and their families, ensuring that care is tailored to the specific risks and needs of each individual. This initiative by the KDCA sets a new precedent for how national health agencies can leverage large-scale cohort data to address complex chronic conditions.